Literature DB >> 8462314

Contraception in older woman.

A Volpe1, M Silferi, A D Genazzani, A R Genazzani.   

Abstract

Oral contraception (OC) in the premenopause has been recently proposed as treatment for control and prevention of the putative symptoms typical of this period of life. Indeed, menstrual cycle disturbances and climacteric symptoms frequently occur at this age. The major aim of normal contraception is resultant maintenance of normal sexual activity. The effects of one OC containing 20 mcg ethinylestradiol and 150 mcg desogestrel (EE/DOG) were studied. Treatment did not significantly modify both lipid metabolism (triglycerides, total cholesterol, HDL, LDL, Apo A, Apo B) and clotting system (fibrinogen, PT, PTT, antithrombin III, fibrinopeptide A). No significant modifications of oral glucose tolerance test (OGGT) occurred after EE/DOG treatment. Also, bone density was not modified during estro-progestinic administration. From our experience, if there are no risk factors such as smoking, obesity or hypertension, the OCs could be used until menopause for absolute contraceptive efficacy, good tolerance and lack of side effects.

Entities:  

Keywords:  Adult; Age Factors; Age Factors--women; Biology; Blood Coagulation Effects; Clinical Research; Clinical Trials; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Effectiveness; Contraceptive Methods; Contraceptive Usage--women; Demographic Factors; Desogestrel; Developed Countries; Ethinyl Estradiol; Europe; Family Planning; Health; Hematological Effects; Hemic System; Italy; Lipid Metabolic Effects; Lipids; Mediterranean Countries; Menopause; Method Acceptability; Middle Aged--women; Oral Contraceptives; Oral Contraceptives, Combined; Osteoporosis; Physiology; Population; Population Characteristics; Public Health; Reproduction; Research Methodology; Research Report; Safety; Skeletal Effects; Southern Europe

Mesh:

Substances:

Year:  1993        PMID: 8462314     DOI: 10.1016/0010-7824(93)90040-e

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  4 in total

1.  Oral contraceptive use and fracture risk around the menopausal transition.

Authors:  Delia Scholes; Andrea Z LaCroix; Rebecca A Hubbard; Laura E Ichikawa; Leslie Spangler; Belinda H Operskalski; Nancy Gell; Susan M Ott
Journal:  Menopause       Date:  2016-02       Impact factor: 2.953

Review 2.  Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review.

Authors:  S L Liu; C M Lebrun
Journal:  Br J Sports Med       Date:  2006-01       Impact factor: 13.800

3.  Oral contraceptive use and bone mineral density in premenopausal women: cross-sectional, population-based data from the Canadian Multicentre Osteoporosis Study.

Authors:  J C Prior; S A Kirkland; L Joseph; N Kreiger; T M Murray; D A Hanley; J D Adachi; Y M Vigna; C Berger; L Blondeau; S A Jackson; A Tenenhouse
Journal:  CMAJ       Date:  2001-10-16       Impact factor: 8.262

Review 4.  Update on hormonal contraception and bone density.

Authors:  Michelle M Isley; Andrew M Kaunitz
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.